

**DRAFT
TOXICOLOGICAL PROFILE FOR
RADON**

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry

September 2008

DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

This information is distributed solely for the purpose of pre dissemination public comment under applicable information quality guidelines. It has not been formally disseminated by the Agency for Toxic Substances and Disease Registry. It does not represent and should not be construed to represent any agency determination or policy.

UPDATE STATEMENT

A Toxicological Profile for Radon was released in 1990. This edition supersedes any previously released draft or final profile.

Toxicological profiles are revised and republished as necessary. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology and Environmental Medicine/Applied Toxicology Branch
1600 Clifton Road NE
Mailstop F-32
Atlanta, Georgia 30333

This page is intentionally blank.

FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public. We plan to revise these documents in response to public comments and as additional data become available. Therefore, we encourage comments that will make the toxicological profile series of the greatest use.

Comments should be sent to:

Agency for Toxic Substances and Disease Registry
Division of Toxicology and Environmental Medicine
1600 Clifton Road NE
Mail Stop F-32
Atlanta, Georgia 30333


Background Information

The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99 499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed ATSDR to prepare toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. The availability of the revised priority list of 275 hazardous substances was announced in the Federal Register on December 7, 2005 (70 FR 72840). For prior versions of the list of substances, see Federal Register notices dated April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); February 28, 1994 (59 FR 9486); April 29, 1996 (61 FR 18744); November 17, 1997 (62 FR 61332); October 21, 1999 (64 FR 56792); October 25, 2001 (66 FR 54014) and November 7, 2003 (68 FR 63098). Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Howard Frumkin M.D., Dr.P.H.
Director
National Center for Environmental Health/
Agency for Toxic Substances and
Disease Registry



Julie Louise Gerberding, M.D., M.P.H.
Administrator
Agency for Toxic Substances and
Disease Registry

QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions.

Primary Chapters/Sections of Interest

Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance's relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, and assesses the significance of toxicity data to human health.

Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by type of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length of exposure (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

NOTE: Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

Pediatrics: Four new sections have been added to each Toxicological Profile to address child health issues:

Section 1.6	How Can (Chemical X) Affect Children?
Section 1.7	How Can Families Reduce the Risk of Exposure to (Chemical X)?
Section 3.8	Children's Susceptibility
Section 6.6	Exposures of Children

Other Sections of Interest:

Section 3.9	Biomarkers of Exposure and Effect
Section 3.12	Methods for Reducing Toxic Effects

ATSDR Information Center

Phone: 1-800-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY) **Fax:** (770) 488-4178

E-mail: cdcinfo@cdc.gov **Internet:** <http://www.atsdr.cdc.gov>

The following additional material can be ordered through the ATSDR Information Center:

Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an exposure history and how to conduct one are described, and an example of a thorough exposure history is provided. Other case studies of interest include *Reproductive and Developmental Hazards*; *Skin Lesions and Environmental Exposures*; *Cholinesterase-Inhibiting Pesticide Toxicity*; and numerous chemical-specific case studies.

Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—*Medical Management Guidelines for Acute Chemical Exposures*—is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. Contact: NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH.

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

Radiation Emergency Assistance Center/Training Site (REAC/TS) provides support to the U.S. Department of Energy, the World Health Organization, and the International Atomic Energy Agency in the medical management of radiation accidents. A 24-hour emergency response program at the Oak Ridge Institute for Science and Education (ORISE), REAC/TS trains, consults, or assists in the response to all kinds of radiation accidents. Contact: Oak Ridge Institute for Science and Education, REAC/TS, PO Box 117, MS 39, Oak Ridge, TN 37831-0117 • Phone 865-576-3131 • FAX 865-576-9522 • 24-Hour Emergency Phone 865-576-1005 (ask for REAC/TS) • e-mail: cooleyp@ornl.gov • website (including emergency medical guidance): <http://www.ornl.gov/reacts/default.htm>.

Referrals

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. Contact: AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: <http://www.aoec.org/>.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. Contact: ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk Grove Village, IL 60007-1030 • Phone: 847-818-1800 • FAX: 847-818-9266.

This page is intentionally blank.

CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHOR(S):

Sam Keith, M.S., C.H.P.

John R. Doyle, M.P.A.

Carolyn Harper, Ph.D.

Moiz Mumtaz, Ph.D.

Oscar Tarrago, M.D., M.P.H., C.H.E.S.

ATSDR, Division of Toxicology and Environmental Medicine, Atlanta, GA

David W. Wohlers, Ph.D.

Gary L. Diamond, Ph.D.

Mario Citra, Ph.D.

Lynn E. Barber, M.S.

Syracuse Research Corporation, North Syracuse, NY

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Research Implementation Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.
4. Green Border Review. Green Border review assures the consistency with ATSDR policy.

This page is intentionally blank.

PEER REVIEW

A peer review panel was assembled in 2008 for radon. The panel consisted of the following members:

1. R. William Field, Ph.D., M.S., Professor, College of Public Health, Department of Occupational and Environmental Health and Department of Epidemiology, University of Iowa, Iowa City, Iowa;
2. Naomi H. Harley, Ph.D., Research Professor, Department of Environmental Medicine, New York University School of Medicine, New York, New York; and
3. Jonathan Samet, M.D., Professor and Chairman, Department of Epidemiology, Bloomberg School of Public Health, The Johns Hopkins University, Baltimore, Maryland.

These experts collectively have knowledge of radon's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

This page is intentionally blank.

CONTENTS

DISCLAIMER	ii
UPDATE STATEMENT	iii
FOREWORD	v
QUICK REFERENCE FOR HEALTH CARE PROVIDERS.....	vii
CONTRIBUTORS	xi
PEER REVIEW	xiii
CONTENTS.....	xv
LIST OF FIGURES	xix
LIST OF TABLES	xxi
1. PUBLIC HEALTH STATEMENT.....	1
1.1 WHAT IS RADON?.....	2
1.2 WHAT HAPPENS TO RADON WHEN IT ENTERS THE ENVIRONMENT?.....	3
1.3 HOW MIGHT I BE EXPOSED TO RADON AND RADON PROGENY?.....	3
1.4 HOW CAN RADON AND RADON PROGENY ENTER AND LEAVE MY BODY?.....	4
1.5 HOW CAN RADON AND RADON PROGENY AFFECT MY HEALTH?.....	4
1.6 HOW CAN RADON AND RADON PROGENY AFFECT CHILDREN?.....	5
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO RADON AND RADON PROGENY?.....	5
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO RADON AND RADON PROGENY?.....	5
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?.....	5
1.10 WHERE CAN I GET MORE INFORMATION?.....	7
2. RELEVANCE TO PUBLIC HEALTH	9
2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO RADON IN THE UNITED STATES.....	9
2.2 SUMMARY OF HEALTH EFFECTS	10
2.3 MINIMAL RISK LEVELS (MRLs).....	12
3. HEALTH EFFECTS	13
3.1 INTRODUCTION	13
3.2 DISCUSSION OF HEALTH EFFECTS OF RADON BY ROUTE OF EXPOSURE.....	16
3.2.1 Inhalation Exposure	16
3.2.1.1 Death.....	25
3.2.1.2 Systemic Effects	26
3.2.1.3 Immunological and Lymphoreticular Effects.....	27
3.2.1.4 Neurological Effects.....	27
3.2.1.5 Reproductive Effects	28
3.2.1.6 Developmental Effects	28
3.2.1.7 Cancer.....	28
3.2.2 Oral Exposure.....	32
3.2.2.1 Death.....	32
3.2.2.2 Systemic Effects	32
3.2.2.3 Immunological and Lymphoreticular Effects.....	32
3.2.2.4 Neurological Effects.....	32
3.2.2.5 Reproductive Effects	32
3.2.2.6 Developmental Effects	32

3.2.2.7	Cancer.....	32
3.2.3	Dermal Exposure.....	33
3.2.3.1	Death.....	33
3.2.3.2	Systemic Effects	33
3.2.3.3	Immunological and Lymphoreticular Effects.....	33
3.2.3.4	Neurological Effects.....	33
3.2.3.5	Reproductive Effects	33
3.2.3.6	Developmental Effects	33
3.2.3.7	Cancer.....	33
3.3	GENOTOXICITY	33
3.4	TOXICOKINETICS	38
3.4.1	Absorption.....	39
3.4.1.1	Inhalation Exposure	39
3.4.1.2	Oral Exposure	42
3.4.1.3	Dermal Exposure	43
3.4.2	Distribution	44
3.4.2.1	Inhalation Exposure	44
3.4.2.2	Oral Exposure	45
3.4.2.3	Dermal Exposure	46
3.4.3	Metabolism.....	46
3.4.4	Elimination and Excretion.....	46
3.4.4.1	Inhalation Exposure	46
3.4.4.2	Oral Exposure	47
3.4.4.3	Dermal Exposure	48
3.4.4.4	Other Routes of Exposure.....	48
3.4.5	Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	48
3.5	MECHANISMS OF ACTION.....	71
3.5.1	Pharmacokinetic Mechanisms.....	71
3.5.2	Mechanisms of Toxicity.....	72
3.5.3	Animal-to-Human Extrapolations	75
3.6	TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS	76
3.7	CHILDREN'S SUSCEPTIBILITY	77
3.8	BIOMARKERS OF EXPOSURE AND EFFECT.....	78
3.8.1	Biomarkers Used to Identify or Quantify Exposure to Radon	79
3.8.2	Biomarkers Used to Characterize Effects Caused by Radon	80
3.9	INTERACTIONS WITH OTHER CHEMICALS.....	81
3.10	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	83
3.11	METHODS FOR REDUCING TOXIC EFFECTS	84
3.11.1	Reducing Peak Absorption Following Exposure.....	84
3.11.2	Reducing Body Burden	84
3.11.3	Interfering with the Mechanism of Action for Toxic Effects	84
3.12	ADEQUACY OF THE DATABASE.....	85
3.12.1	Existing Information on Health Effects of Radon	85
3.12.2	Identification of Data Needs.....	87
3.12.3	Ongoing Studies	92
4.	CHEMICAL, PHYSICAL, AND RADIOLOGICAL INFORMATION.....	93
4.1	CHEMICAL IDENTITY	93
4.2	PHYSICAL, CHEMICAL, AND RADIOLOGICAL PROPERTIES.....	93

5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	101
5.1 PRODUCTION.....	101
5.2 IMPORT/EXPORT.....	102
5.3 USE.....	102
5.4 DISPOSAL	104
6. POTENTIAL FOR HUMAN EXPOSURE	105
6.1 OVERVIEW	105
6.2 RELEASES TO THE ENVIRONMENT	109
6.2.1 Air	110
6.2.2 Water.....	111
6.2.3 Soil	112
6.3 ENVIRONMENTAL FATE.....	112
6.3.1 Transport and Partitioning.....	112
6.3.2 Transformation and Degradation	115
6.3.2.1 Air	115
6.3.2.2 Water.....	116
6.3.2.3 Sediment and Soil	116
6.3.2.4 Other Media	116
6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	116
6.4.1 Air	116
6.4.2 Water.....	118
6.4.3 Sediment and Soil	120
6.4.4 Other Environmental Media.....	121
6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE.....	121
6.6 EXPOSURES OF CHILDREN	124
6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	126
6.8 ADEQUACY OF THE DATABASE.....	126
6.8.1 Identification of Data Needs	127
6.8.2 Ongoing Studies	129
7. ANALYTICAL METHODS	131
7.1 BIOLOGICAL MATERIALS	131
7.2 ENVIRONMENTAL SAMPLES	133
7.3 ADEQUACY OF THE DATABASE.....	137
7.3.1 Identification of Data Needs	140
7.3.2 Ongoing Studies	140
8. REGULATIONS, ADVISORIES, AND GUIDELINES.....	141
9. REFERENCES	147
10. GLOSSARY	209

APPENDICES

A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS A-1

B. USER'S GUIDE B-1

C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS..... C-1

D. OVERVIEW OF BASIC RADIATION PHYSICS, CHEMISTRY, AND BIOLOGY D-1

E. INDEX..... E-1

LIST OF FIGURES

3-1. Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance.....	51
3-2. Compartment Model to Represent Particle Deposition and Time-Dependent Particle Transport in the Respiratory Tract.....	54
3-3. Reaction of Gases or Vapors at Various Levels of the Gas-Blood Interface.....	57
3-4. The Human Respiratory Tract Model: Absorption into Blood.....	62
3-5. Simplified Version of the Human Respiratory Tract Model (HRTM)	64
3-6. Schematic Diagram of the NAS (1999b) PBPK Model Developed to Describe the Fate of Radon within Systemic Tissues.....	66
3-7. Khursheed (2000) PBPK Model for Inhalation and Ingestion of Radon Gas.....	69
3-8. Conceptual Model of the Biology Leading From Alpha Irradiation of Cells by Radon and Radon Progeny to Tumor Development.....	74
3-9. Existing Information on Health Effects of Radon	86
4-1. ²³⁸ U Decay Series Showing Sources and Decay Products.....	95
4-2. ²³² Th Decay Series Showing Sources and Decay Products	98
4-3. ²³⁵ U Decay Series Showing Sources and Decay Products.....	100
6-1. Frequency of NPL Sites with Radon Contamination.....	106

This page is intentionally blank.

LIST OF TABLES

3-1. Selected Characteristics and Exposure Data for Individual Miner Cohort Studies Included in the Analysis of Pooled Data from the Individual Studies, and Lung Cancer Mortality Rates and Relative Risks by Cumulative WLM for Pooled Data.....	20
3-2. Selected Results from Analysis of Pooled Data from 11 Mining Cohorts ^a , Based on Deciles of Case Exposures That Were Each Under 100 WLM.....	21
3-3. Selected Characteristics of Study Subjects, Exposure Estimates, and Odds Ratios for Lung Cancer from Combined Analysis of Seven North American Residential Case-control Studies (Using a 5–30-year Exposure Time Window).....	23
3-4. Relative Risk and Excess Relative Risk of Lung Cancer by Radon Level in Homes 5–34 Years Previously, Estimated from the Pooled Data for 13 European Residential Case-control Studies.....	24
3-5. Genotoxicity of Radon and Radon Progeny <i>In Vivo</i>	34
3-6. Genotoxicity of Radon and Radon Progeny <i>In Vitro</i>	35
3-7. Reference Respiratory Values for a General Caucasian Population at Different Levels of Activity.....	55
3-8. Reference Values of Parameters for the Compartment Model to Represent Time-dependent Particle Transport from the Human Respiratory Tract.....	59
3-9. Parameters in the NAS (1999b) PBPK Model	68
3-10. Parameters in Khursheed (2000) PBPK Model for Radon Gas.....	70
4-1. Chemical Identity of Radon.....	94
4-2. Physical and Chemical Properties of Radon.....	96
4-3. Radioactive Properties of ²²² Rn and Its Short-lived Progeny	99
7-1. Analytical Methods for Determining Radon Progeny in Biological Samples.....	132
7-2. Analytical Methods for Determining Radon and Progeny in Environmental Samples	138
8-1. Regulations, Advisories, and Guidelines Applicable to Radon.....	143